NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
You may also be interested in...
Nicotine Lozenge Underdosing Discouraged In GSK Smoking Cessation Study
Smokers should be encouraged to use at least seven to eight nicotine lozenges per day when attempting to quit smoking, researchers suggest in the June 10 Archives of Internal Medicine
Nicotine Lozenge Underdosing Discouraged In GSK Smoking Cessation Study
Smokers should be encouraged to use at least seven to eight nicotine lozenges per day when attempting to quit smoking, researchers suggest in the June 10 Archives of Internal Medicine
Nicotine Lozenge Underdosing Discouraged In GSK Smoking Cessation Study
Smokers should be encouraged to use at least seven to eight nicotine lozenges per day when attempting to quit smoking, researchers suggest in the June 10 Archives of Internal Medicine